Takeru Funakoshi

16PUBLICATIONS
72CO-AUTHORS
Oncology and carcinogenesis not elsewhere classifiedPredictive and prognostic markersMolecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Respiratory diseases
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (16)

|Mar 04, 2026
Nivolumab for unresectable cutaneous epithelial malignancies: an open-label, single-arm, multi-centre, phase II trial (NMSC-PD1).

Yoshio Nakamura, Naoya Yamazaki, Kenjiro Namikawa

|Apr 04, 2025
Adjuvant Anti-PD-1 Monotherapy Versus Observation for Stage III Acral Melanoma of the Sole: A Multicenter Retrospective Study in Japanese Patients.

Shigeru Koizumi, Naoya Yamazaki, Yuki Ichigozaki

|Jun 01, 2024
Phase II clinical trial of docetaxel and trastuzumab for HER2-positive advanced extramammary Paget's disease (EMPD-HER2DOC).

Ikuko Hirai, Keiji Tanese, Yoshio Nakamura

|Jan 29, 2024
Eribulin for patients with metastatic extramammary Paget disease: Study protocol for a single-arm phase II trial.

Takuya Maeda, Teruki Yanagi, Keiko Tokuchi

|Apr 25, 2022
Management and outcomes of hydronephrosis in patients with metastatic extramammary Paget's disease: A retrospective analysis.

Takayuki Fusumae, Keitaro Fukuda, Ikuko Hirai

|Dec 10, 2021
Imatinib mesylate in combination with pembrolizumab in patients with advanced KIT-mutant melanoma following progression on standard therapy: A phase I/II trial and study protocol.

Ikuko Hirai, Keiji Tanese, Keitaro Fukuda

Pageof 3

Frequent Collaborators

3 joint publications

Keiji Tanese

3 joint publications

Yoshio Nakamura

3 joint publications

Ikuko Hirai

3 joint publications

Keitaro Fukuda